OraVax preclinical data

ORVX (Cambridge, Mass.) presented preclinical data on its vaccine for H. pylori bacterial infection of the stomach.

As reported at the European Helicobacter pylori Study Group in Edinburgh, Scotland, oral or intragastric administration of the vaccine to mice in four weekly doses of >= 5 µg protected up to 100 percent against challenge with H. felis, with protection evident for up to seven months. ...